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Abstract
Introduction: Serum lipoprotein levels change during hospitalization and effect patient’s 
outcome in case of sepsis. The aim of this study was to investigate the prognostic values of 
the serum levels of lipids in Intensive Care Unit (ICU) admitted patients.
Methods: Intensive Care Unit admitted patients with various etiologies were enrolled 
in this study. Serum lipid level was collected on the first and seventh day of admission. 
Clinical outcome and baseline characteristics, including age, gender, cause of admission, 
length of ICU stay, and discharge or death were monitored prospectively in a short cohort.
Results: A total of 108 patients were enrolled in this study. The overall mortality rate 
was 45%. The average duration of hospitalization at the ICU was significantly lengthier 
in the un-survived group. Lipid profile had a similar pattern in both genders. Triglyceride 
level seemed to increase from Day one to Day seven. These changes were observed in 
both unsurvived and survived group and were not significantly different. A considerable 
decline of 24% in High Density Lipoprotein (HDL) was detected among unsurvived 
patients. The mean value of TG on day seven among unsurvived patients was significantly 
higher than that of the survived group. Receiver Operating Characteristic (ROC) 
curve illustrated the higher diagnostic ability of HDL level in comparison with other 
parameters. On day seven, serum HDL cutoff value of 32 (sensitivity 75%; specificity 
60%) was observed for predicting the mortality.
Conclusions: Cholesterol is essential for integrity as well as the function of the cell 
membrane, therefore, dyslipidemia occurring during hospitalization may negatively 
influence the outcome. Consequently, changes in lipid profile could be a prognostic 
biomarker for predicting mortality in ICU-admitted patients.
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 Patients admitted to the intensive care unit experience mul-
tiple underlying disorders that can increase the duration of 
hospitalization and the risk of mortality in case of insufficient 
medical care. The severity of the patient and prognosis could 
be assessed using newly designed technologies for healthcare. 
The necessity of choosing a highly efficient approach to pre-
dict the patients’ clinical prognosis and outcome in a short 
time at the ICU is still a challenge. One of these methods, 
which is already commonly used, is Acute Physiological and 
Chronic Health Evaluation (APACHE) at the Intensive Care 
Units (ICU) [1]. This method can calculate the mortality 
risk and the duration of hospitalization at the ICU through 
providing information, such as previous experience of illness, 
vital signs and blood indices, including electrolytes, arterial 
blood gas, and etc. This criterion is very time consuming with 
the calculation of more than 17 parameters, and its software 
is not widely available [2]. Therefore, efforts are being made 
to use methods that, at the same time, provide the necessary 
efficiency, reliability, and ease of use.
Lipoproteins, especially High-Density Lipoprotein (HDL), 
can be considered as an anti-inflammatory agent, which 
modulates immune responses due to inhibiting immune sys-
tem activity [3]. Also, it has been reported that infection and 
inflammation affect lipid profile [4], which is in the form of 
a decrease in lipoproteins or triglycerides. It has also been in-
dicated that insulin resistance is created in the field of inflam-
mation and infection, which in addition to increasing blood 
glucose, increases Triglyceride (TG) and decreases HDL and 
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Low-Density Lipoprotein (LDL) [5, 6]. Changes in the me-
tabolism of lipoproteins during inflammation and infection 
can increase TG levels due to increased Very Low-Density 
Lipoproteins (VLDL) production or reduced clearance in 
the liver [7]. Indeed, HDL induces production of antioxidant 
proteins, such as Platelet Activating Factor-Acetyl Hydrolase 
(PAF-AH), transferrin, and serovoluclamine Paraoxonase 
(PON) [8]. Hence, lipid profile fluctuation could be em-
ployed as a biomarker for evaluating other situations, such 
as blood glucose control [9]. Since, in the diabetic patients, 
there was a linear relationship between TG serum level and 
mortality.  Moreover, LDL and HDL of less than 20 mg/dl 
and15 mg/dl respectively, increased mortality [10].
Furthermore, the protective effect of lipoproteins and apo-
proteins has been confirmed by neutralization of antigenicity 
of Lipopolysaccharides (LPS), as well as reduction of adhe-
sion molecules; thus, belonging to the diagnostic value of lip-
id profile, they are considered as therapeutic agents as well 
[10, 11]. In this situation, HDL detaches LPS-binding to the 
monocyte membrane, while LDL, apoB, and VLDL neutral-
ize free LPS in the serum by attachment [12]Chulalongkorn 
University and King Chulalongkorn Memorial Hospital, 
Bangkok, Thailand. Effects of infection and inflammation on 
lipid and lipoprotein metabolism: mechanisms and conse-
quences to the host.
Accordingly, serum lipoprotein levels and its alterations are 
appropriate factors for patient prognosis evaluation, especial-
ly since serum cholesterol, TG, HDL, and LDL levels against 
APACHE score are dependent on the quality of care provid-
ed at the ICU.
In 2008, Carlo Chiario reported considerable changes in 
lipid profiles in SEPSIS [13]. However, Yassin Arabi et al. 
conducted a study in 2013, in which they did not report a 
relationship between changes in TG and patients mortality 
[14]. The purpose of this study was to introduce a method 
to predict clinical prognosis in ICU patients with regards to 
both simplicity and availability [11].
MeThODS
This study was a prospective analysis of a cohort research at 
the ICU; admitted patients at a tertiary university medical 
center (Labbafinejad hospital) in Tehran, Iran.  The study 
protocol was reviewed and approved by the ethical com-
mittee of Shahid Beheshti University of Medical Sciences 
(1394/11/13-425). Informed consent was obtained from 
patients or their next of kin. Among patients admitted to the 
ICU with various etiologies, patients were excluded if they 
met specific criteria, including  age of less than 18 years, preg-
nancy,  patients with respiratory failure and transplantation, 
history of dyslipidemia, or a history of steroid within the pre-
vious seven days and received serum containing intera-lipid 
or Total Parenteral Nutrition (TPN). Finally, a total of 108 
ICU patients were enrolled in the study between March 2017 
and August 2017. 
All eligible patients in this study were managed, according to 
their chief complaint and specific disorders. For each patient, 
demographic data, including age and gender, were collected 
and also, Acute Physiology and Chronic Health Evaluation 
II (APACHE II) score, Glasgow Coma Scale (GCS) and 
laboratory data, including cholesterol, TG, HDL, LDL, and 
serum levels, were gathered on the first and seventh day of 
admission.
The levels of total cholesterol (normal range: 100 to 220 mg/
dL), HDL (normal range: 40 to 86 mg/dL), TG (normal 
range: 44 to 240 mg/dL), LDL (normal range: 70 to 169 mg/
dL), were measured using commercial kits with an automat-
ed analyzer (Hitachi 7600 to 200-DDP, Hitachi Ltd., Tokyo, 
Japan). 
Statistical Analysis
To analyze the gathered data, continuous variables were as-
sessed by Kolmogorov Spinoff test for normal distribution. 
Considering P > 0.5, variables were compared using stu-
dent’s t-test and were presented as the mean ± standard de-
viation. For categorical variables, Pearson’s chi-squared test 
or Fisher’s exact test were chosen, and the frequencies were 
reported. The impact of serum lipid levels in two categories, 
including normal versus low level on survival, was evaluated 
using Cox proportional hazard models. Receiver Operating 
Characteristic (ROC) curve was used to examine the capaci-
ty of serum HDL and LDL cholesterol level in differentiating 
the status of survival. The Area under the Curve (AUC) and 
95% Confidence Interval (CI) were reported. All statistical 
analyses were performed using the SPSS version 20 software 
(SPSS, Chicago, IL, USA).
ReSULTS
The total number of patients was 108, of which 47 (43.5%) 
were females and 61 (56.5%) were males. The baseline char-
acteristics of the patients are presented in Table 1. The mean 
age of the patients was 71 ± 12.1 years, and the average dura-
tion of hospitalization at the ICU was 12.15 ± 4.7 and 7.4 ± 
2.4 days in survived and un–survived cases, respectively. The 
overall mortality rate was 45%.
Lipid profile had a similar pattern in both genders. There was 
a significant difference in both duration of admission and 
GCS between survived and un-survived patients. The most 
prevalent underlying diseases were Chronic Obstructive Pul-
monary Disease (COPD), End Stage Renal Disease (ESRD), 
and cancer with a rate of 24.1%, 22.2%, and 11.1% respective-
ly. Moreover, 21.3% of all patients experienced sepsis.
In total, the highest death rates belonged to cancer and 
ESRD with a prevalence of 66% and 58%, respectively. How-
ever, COPD patients achieved a great level of improvement 
(73%). The baseline characteristics of the patients are pre-
sented in Table 1, and in Table 2, the mean level of serum lip-
id profile is compared. According to the analysis of the data, 
there was a reverse correlation between the ages of patients 
with blood TG level (correlation coefficient of -0.37 with P < 
0.001). This correlation was not approved in the serum cho-
lesterol level.
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Table 1. General Characteristics of the Patients in both Groups
Total, N = 108 Survivors, N = 60 UN-Survivors, N = 48 P Value
Male Gender 56.5 61.7% 50% N/S
Age 12.1 ± 71 18.02 ± 69.75 14.69 ± 72.48 N/S
Duration of Admit 4.4 ± 9.5 2.4 ± 7.4 4.7 ± 12.15 0.01
GCS 2 ± 10 1 ± 12 2 ± 7 0.01
COPD (24.1) 26 (73.1) (26.9) 0.01
Cancer (11,1) 12 (33.3) (66.7) N/S
Sepsis (21.3) 23 (39.1) (60.9) N/S
DhF (6.5) 7 (71.4) (28.6) 0.01
CKD/eSRD (22.2) 24 (41.7) (58.3) N/S
PTe (8.3) 9 (55.6) (44.4) N/S
Others (6.5) 7 (42) (58) N/S
Data in table are presented as Mean ± SD or Number (%) or (%)
Abbreviations: GCS: Glasgow Coma Scale; COPD: Chronic Obstructive Pulmonary Disease; DHF: Decompensated Heart 
Failure; CKD: Chronic Kidney Disease; ESRD: End Stage Renal Disease; PTE: Pulmonary Thromboemboli
Table 2. Lipid Profile of Serum on Day One and Seven
Survivors, N= 60 Un-survivors, N= 48 P Value
TG1 34.64 ± 107.78 76.7 ± 128.60 0.86
TG7 34.43 ± 111.55 68.20 ± 138.38 0.01
 Pared t-test N/S N/S
 Cholestrol-1 41.91 ± 128.83 38.34 ± 125 0.62
Cholestrol-7 32.99 ± 127.17 40.34 ± 119.81 0.23
Pared t-test N/S N/S
LDL1 22.33 ± 69.21 22.32 ± 68.35 0.84
LDL7 21.23 ± 68.78 24.16 ± 63.89 0.26
Pared t-test N/S N/S
hDL1 15.86 ± 37.16 13.4 ± 32.18 0.08
hDL7 13.57 ± 37.28 10.3 ± 24.45 0.01
Pared t-test N/S P-value: 0.04
Abbreviations: N/S: Not significant; TG: triglyceride(s); HDL: high-density lipoprotein; LDL: low-density lipoprotein
Figure 1. Changes in Lipid Profile over Time after ICU Admission
Abbreviations: TG: Triglyceride(s); HDL: High-density lipoprotein; LDL: Low-density lipoprotein
*Significance difference (P < 0.05)
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Figure 2. Receiver Operating Characteristic Curve of Serum HDL Cholesterol, LDL Cholesterol, and HDL Cholesterol on Day One and 
Seven for Prediction of Survival of ICU Admitted Patients
a: Serum Lipid Profile on day one; b: Serum Lipid Profile on day seven; c: The difference obtained during the seven-day follow up. As the 
figure shows, the most area under the curve belongs to HDL 7.
Triglyceride level seemed to increase from Day one to Day 
seven. These changes were observed in both populations and 
were not significantly different. However, the mean value of 
TG on day seven among unsurvived patients was significant-
ly higher than that of the survived group (Table 2).
The changes in the mean level of LDL, as well as cholester-
ol over seven days of follow up, were fairly stable (Table 2). 
The HDL decreased 25% on day seven of admission in un-
survived patients whereas it was steady among survived ones. 
Moreover, it was found that there was a significant correla-
tion between the duration of hospitalization at the ICU with 
HDL on day seven and the correlation coefficient (P < 0.001, 
-0.24) (Figure 1).
The ROC curve illustrated the higher diagnostic ability of 
HDL level on the seventh day in comparison with other pa-
rameters as a survival marker. On day seven, a serum HDL 
best cutoff value of 32 (sensitivity 75%; specificity 60%; AUC 
70, 95% CI) and a serum LDL cholesterol best cutoff value 
of 60 (sensitivity, 70%; specificity, 60%; AUC 68, 95% CI) 
were selected by ROC curve for efficacy analysis (Figure 2). 
Using the new parameter obtained from age multiplication 
by the deduction of HDL level during seven days, improved 
both sensitivity and specificity. In the range of -100 to -200, 
sensitivity and specificity were 80 and 65, respectively.  The 
area under the curve and diagnostic ability of the levels of 
TG, cholesterol, HDL, and LDL, as well as changes, occurred 
in the lipid profile was not considerable at all.
DISCUSSION
The current study indicated a correlation between serum li-
poprotein levels and the short-term clinical outcome of the 
patients. Some of these findings have been mentioned in 
previous studies, and the current study confirmed this re-
lationship as well. Based on this study, in patients with the 
acute phase of the disease, lower serum HDL level was asso-
ciated with poor prognoses condition, and it was found that 
patients, who died during hospitalization, had higher levels 
of triglycerides on the first day of hospitalization, yet lower 
HDL than those with longer survival. The alteration in the 
amount of lipid profile would also increase in the course of 
hospitalization. In this regard, Ben Weil et al. reported a re-
lationship between the reductions of serum lipoproteins and 
death in patients with Systemic Inflammatory Response Syn-
drome (SIRS) at the ICU [15]. The patients enrolled in the 
current study had various complaints, and in all study groups, 
the same pattern of lipid profile changes was observed.
In a study conducted by Al-Dawoodet al. in 2013, the de-
crease in blood lipoprotein levels in poor prognostic patients 
was common and total cholesterol level, as well as HDL, was 
reversely correlated with mortality rate [14]. However, there 
was no significant relationship between total cholesterol and 
mortality in the current study. The findings of the current 
study also confirmed the results of the study conducted by 
Chien et al. in 2015, which indicated a relationship between 
decrease in HDL-lipoprotein level and mortality, and the 
total decline from the first day to the seventh day has prog-
nostic value [16]. In their study, a cutoff point of 17 mg/dL 
HDL had a diagnostic value of 83.3% sensitivity and 94.7% 
specificity while the current study indicated the best sensi-
tivity (75%) and specificity (60%) at the level of 32 mg/dL 
of HDL. The population size in the current study was 108 
patients with heterogeneous diagnoses, and the decline that 
occurred in the HDL cholesterol level was 24% in unsur-
vived patients. On the contrary, in the study implemented 
by Chien et al., there was a total of 40 patients with various 
etiologies and the decline was more than 50%. This consider-
able decline in lipid profile at the ICU was multifactorial and 
should be taken into account.
The anti-inflammation role of lipoproteins has led researchers 
to administer them as a therapeutic option in poor progno-
ses patients. High Density Lipoprotein injections in animal 
models reduce mortality and, in humans, they also inhibit the 
activity of pro-coagulant and endotoxins, yet increase the risk 
of fungal infections at higher doses [17]. Other clinical trials, 
including prescribing   (soybean oil) and   (fish oil) and olive 
oil, have revealed that enriched oils containing high   and low 
would reduce inflammation and improve the ARDS condi-
tion [18, 19].
It has also been recently shown that there is a significant in-
verse correlation between lipid profile changes and APACHE 
score among ICU admitted patients [20, 21]. In another 
point of view, all ICU admitted patients inevitably need re-
spiratory care. Both LDL and HDL effect local pulmonary 
cholesterol biosynthesis by supplying cholesterol to lung-res-
ident cells [22].
Motafaker Azad, et al
42
International Journal of Cardiovascular Practice 
Besides, HDL acts as the antioxidant for alveolar type II 
pneumocytes and stimulus production of surfactant as well 
as lung fibroblasts proliferation, which are affected by high 
serum cholesterol level due to altering compositions [23]. In 
this regard, several studies have indicated the impact of cho-
lesterol targeted medications on respiratory disorders such as 
asthma, COPD, and fibrosis. Among modified items induced 
by these agents, reduction in BAL eosinophils, reduction of 
lung injury, and collagen deposition, reduction of cytokines 
and inflammation and so on are considerable [21, 22, 24].
CONCLUSION
Cholesterol is essential for integrity as well as the function 
of the cell membrane thus; dyslipidemia occurring during 
hospitalization may negatively influence the outcome. Con-
sequently, changes in lipid profile could be a prognostic 
biomarker, an alternative or an additive parameter to the im-
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